Literature DB >> 15635614

Bronchiolitis obliterans in children.

Geoffrey Kurland1, Peter Michelson.   

Abstract

Bronchiolitis obliterans (BO) in children is a relatively rare diagnosis. The increase in lung and bone marrow transplantation in children, however, has led to a heightened interest in BO, as this is one of the important complications of those procedures. This article will discuss BO as an entity that can follow any of several illnesses or toxic exposures, in addition to following allogeneic lung or bone marrow transplantation. The complex and incompletely understood pathology, pathogenesis, and molecular pathology involved in BO remain the subject of ongoing investigations. As the prognosis for BO is uncertain and treatment is often unsuccessful, the continued need for the recognition of surrogate markers for BO in patients at risk and the development of better forms of therapy are paramount. This review will describe our current understanding of BO, and will call attention to those research areas that require continuing efforts in order to prevent or treat this entity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15635614     DOI: 10.1002/ppul.20145

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  17 in total

1.  Insights into post-infectious bronchiolitis obliterans in children.

Authors:  K J Smith; L L Fan
Journal:  Thorax       Date:  2006-06       Impact factor: 9.139

Review 2.  Managing wheeze in preschool children: How difficult can it be?

Authors:  Shaikh M Iqbal
Journal:  Sudan J Paediatr       Date:  2012

3.  Feasibility of laparoscopic Nissen fundoplication after pediatric lung or heart-lung transplantation: should this be the standard?

Authors:  Chi Zheng; Timothy D Kane; Geoffrey Kurland; Kathy Irlano; Jonathan Spahr; Douglas A Potoka; Peter D Weardon; Victor O Morell
Journal:  Surg Endosc       Date:  2010-06-29       Impact factor: 4.584

4.  Quantitative computed tomography assessment of graft-versus-host disease-related bronchiolitis obliterans in children: A pilot feasibility study.

Authors:  Hyun Gi Kim; Hyun Joo Shin; Yoon Hee Kim; Myung Hyun Sohn; Chuhl Joo Lyu; Myung-Joon Kim; Kyung Won Kim; Mi-Jung Lee
Journal:  Eur Radiol       Date:  2015-03-26       Impact factor: 5.315

5.  Quantitative CT lung densitometry as an obstructive marker for the diagnosis of bronchiolitis obliterans in children.

Authors:  Hye Jin Lee; Seong Koo Kim; Jae Wook Lee; Soo Ah Im; Nack-Gyun Chung; Bin Cho
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

6.  Diagnostic value of antineutrophil cytoplasmic antibodies in children with bronchiolitis obliterans.

Authors:  Dehui Chen; Na Xie; Yuneng Lin; Zifeng Yang; Wenkuan Liu; Shangzhi Wu; Jingbin Chen; Xiaoan Pan; Shaolin Yang; Yong Cai
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

Review 7.  Pediatric lung transplantation: promise being realized.

Authors:  Carol Conrad; David N Cornfield
Journal:  Curr Opin Pediatr       Date:  2014-06       Impact factor: 2.856

8.  Ventilation/perfusion scintigraphy in children with post-infectious bronchiolitis obliterans: a pilot study.

Authors:  Bo-Qia Xie; Wei Wang; Wen-Qian Zhang; Xin-Hua Guo; Min-Fu Yang; Li Wang; Zuo-Xiang He; Yue-Qin Tian
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

9.  Follow-up on pediatric patients with bronchiolitis obliterans treated with corticosteroid pulse therapy.

Authors:  Silvia Onoda Tomikawa; Fabíola Villac Adde; Luiz Vicente Ribeiro Ferreira da Silva Filho; Claudio Leone; Joaquim Carlos Rodrigues
Journal:  Orphanet J Rare Dis       Date:  2014-08-15       Impact factor: 4.123

10.  Pseudomonas aeruginosa Induced Airway Epithelial Injury Drives Fibroblast Activation: A Mechanism in Chronic Lung Allograft Dysfunction.

Authors:  L A Borthwick; M I Suwara; S C Carnell; N J Green; R Mahida; D Dixon; C S Gillespie; T N Cartwright; J Horabin; A Walker; E Olin; M Rangar; A Gardner; J Mann; P A Corris; D A Mann; A J Fisher
Journal:  Am J Transplant       Date:  2016-02-26       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.